CLINICAL IMPROVEMENT IN PATIENTS WITH EXERCISE INDUCED PULMONARY ARTERY HYPERTENSION AFTER 6 MONTHS OF PHOSPHODIESTERASE-5 INHIBITORS OR ENDOTHELIAL RECEPTOR ANTAGONISTS OR BOTH

被引：0
|
作者：
Mannem, Santhosh R. [1 ]
Salamon, Jason [1 ]
Gunda, Sampath [1 ]
Iqbal, Muhammed [1 ]
Bhandari, Manoj [1 ]
Mazurek, Jeremy [1 ]
Zolty, Ronald [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 63卷 / 12期
关键词：
D O I：
10.1016/S0735-1097(14)61663-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1197-357
引用
收藏
页码：A1660 / A1660
页数：1
相关论文
共 33 条
  • [31] Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors
    Hoeper, Marius M.
    Klinger, James R.
    Benza, Raymond L.
    Simonneau, Gerald
    Langleben, David
    Naeije, Robert
    Corris, Paul A.
    RESPIRATORY MEDICINE, 2017, 122 : S18 - S22
  • [32] Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study
    Takeru Kashiwada
    Yosuke Tanaka
    Toru Tanaka
    Tetsuya Okano
    Yoshinobu Saito
    Masahiro Seike
    Mitsunori Hino
    Hiroshi Kimura
    Akihiko Gemma
    BMC Pulmonary Medicine, 24
  • [33] Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention-prospective, single-center, randomized, parallel-group study
    Kashiwada, Takeru
    Tanaka, Yosuke
    Tanaka, Toru
    Okano, Tetsuya
    Saito, Yoshinobu
    Seike, Masahiro
    Hino, Mitsunori
    Kimura, Hiroshi
    Gemma, Akihiko
    BMC PULMONARY MEDICINE, 2024, 24 (01)
1234